Glenmark Pharmaceuticals Announces Q2FY26 Results: Revenue Up by 76.1% YoY, EBITDA Margin at 39%, PAT Margin at 10.1%

Glenmark Pharmaceuticals Ltd. has announced its financial results for the second quarter ended September 30, 2025. The company's consolidated revenue was at Rs. 60,469 Mn, a 76.1% YoY increase. EBITDA was Rs. 23,596 Mn, up 292% YoY, with an EBITDA margin of 39%. Profit After Tax (PAT) was Rs. 6,104 Mn, up 72.2% YoY, with a PAT margin of 10.1%. The North America business grew by 7.4% (Net of the out-licensing income of the I1SB 2001 deal) and Europe revenue was up by 8.5% YoY. However, the India Formulations revenue declined by 87.1%.